Clinical Trials Logo

Recurrent Glioblastoma clinical trials

View clinical trials related to Recurrent Glioblastoma.

Filter by:

NCT ID: NCT00390299 Completed - Clinical trials for Recurrent Glioblastoma

Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

Start date: October 23, 2006
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of carcinoembryonic antigen-expressing measles virus (MV-CEA) in treating patients with glioblastoma multiforme that has come back. A virus, called MV-CEA, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.

NCT ID: NCT00250887 Completed - Clinical trials for Recurrent Glioblastoma

Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy). Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR). EGFR is elevated in more than 50% of malignant gliomas. At recurrence, secondary surgery and pre- and postoperative Gefitinib is offered to patients in good performance status. Clinical outcome of patients and correlation to translational research will be evaluated.

NCT ID: NCT00102648 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide

Start date: December 21, 2004
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lonafarnib when given together with temozolomide and to see how well they work in treating patients with glioblastoma multiforme that is has come back or did not respond to previous treatment with temozolomide. Lonafarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lonafarnib together with temozolomide may kill more tumor cells.